Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have given up on you long time ago. After reading over four hundreds publications as you bragged about, you have n't come up with anything seminal. All you are trying to do is nagging and casting negativity. You are just a fake long with ulterior motive. If I can see through your dirty trick, every long can.
Keep playing.
I am 100% right on this one. Did I tell you that NWBO and UCLA can play with dendritic cells like a great master?
Did you see Anthony Wang's clinical trial with H3 G34 as tumor specific target? You know why it is so special. This tumor-specific antigen is inside the cancer cell and none of precision medicine is going to work since precision medicine can only target antigens on the surface of cancer cells. Only t cell receptor therapy can target this tumor specific antigen. UCLA can pulse dendritic cells with specific peptides so that activated t cells can target the specific antigen inside cancer cells while sparing normal cells. Do you have clue the significance of what UCLA did? Enlighten me if you can.
Find another angle to deceive.
It doesn't matter how many years you have been keeping an eye on APCEDEN. Just like it doesn't matter how many papers you claimed you had read. If APCEDEN were able to present many antigens as you believe, the company would have sung like a canary many years ago. BPs should have acquired the company many years ago. I mentioned to you several times four world-renowned scientists who did clinical trials on dendritic cells and none of them made breakthrough. They simply cannot make DCs present the number of tumor-associated antigens to immune system on the same magnitude like what NWBO has achieved. BTW, could you remind me of their names?
You should know DCs are antigen presenting cells. APCEDEN is doing the same in presenting tumor-associated antigens too. But how many can APCEDEN present to immune system? Very few. Do you get it now?
You still haven't understood the fundamental difference between DCVax-L (ATL-DC) and other DC vaccines like the one you were talking about. What matters the most is the number of tumor-associated antigens that DCs can present to immune system. Can you enlighten me how many tumor-associated antigens Apceden can present? If Apceden had significant efficacy, GBM patients would travel to India to receive the treatment through compassionate program by paying much less.
But on this planet this is only one unique technology that can make dendritic cells digest tumor lysate and then present hundreds of tumor-associated antigens to immune system. Do I need to remind you which company owns the technology? Are you going to say again that ATL-DC is not DCVax-L?
Those clueless minions have no idea about how revolutionary the technology is. But you should have much better understanding about how revolutionary and disruptive DCVax-L is.
Focusing only on one specific target like GBM is far too conservative. The immediate and enormous value will come from DCVax-L being adopted as a platform for drug and vaccine development. There are going to be multiple franchise deals with BPs.
Read again the following to see if my post is BS.
https://pubmed.ncbi.nlm.nih.gov/37192158/
Horse,
I don't think it has any connection to DCVax-L. It is just one type of treatment under phase 1 trial.
IMO, one characteristic of GBM is that it likes grass weed which has deep roots into surrounding normal tissue. Surgery can take out of the majority of tumor. I don't think it is easy to get rid of the roots. But activated t cells loaded with tumor associated antigens can wipe out all the elusive cancer cells.
Theragnostics Ltd
https://theragnostics.com/
Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma (CITADEL-123)
https://clinicaltrials.gov/study/NCT06650605
You do know that poly-iclc must be combined with DCVax-L, don't you? Now enlighten the longs with your critical thinking skills what are the implications of the following news. I guess you cannot elaborate. Otherwise you wouldn't do this sp prediction game, which strikes me you have nothing to contribute.
https://www.vcpost.com/articles/126732/20240521/partner-with-biotechnologys-oncovir-to-build-a-healthier-future-for-all.htm
The final checkmate is closer as each day goes by. You do know this. Right?
You know why you get stuck in the trap? You didn't do your own homework and just listened to AF. Do you still believe his BS that ATL-DC is not DCVax-L? I assume by now you should know you were brainwashed by his shitty claim.
Here is a piece of homework for you which concerns your financial future big way. Tell the longs which company has almost all the inhibitors that can modulate tumor microenvironment.
If it walks like a duck, quacks like a duck, it is a duck!
Why do you want to guess the price on something with potential value beyond measure?
I thought someone who read hundreds of peer-reviewed papers would agree that DCVax-L would and should be the standard platform for the development of drug and vaccine. All those BPs which have precision medicine will have franchise deals with the company. Instead of guessing sp, I suggest you guess if the scenario I projected could be real.
Inept management?
How many milestones has the company reached? How many years has the company survived on OTC? You do know that total assets of 7 MMs are multiple times of GDP of a mid-size country, don't you?
Did you see Dr. Liau joined the SAB of another company? You don't think Dr. Liau has much better judgment on the management of the company than you?
You are scared to see the reality, are you not?
You don't think I have done my homework? How could I know Nina Bhardwaj, I. Melero, Carolyn Britten, Lisa Butterfield if I didn't do my homework?
What you mentioned is frivolous. Basically you still treat DCVax-L as something mediocre which consists of other parts of your portfolio. Now you can search again to see what should be the last hurdle to cure GBM for DCVax-L to overcome.
DCVAX-L is the biggest breakthrough in medicine ever! Don't bet against unless you want to go broke.
TJ,
For the safety of your financial future, you have to equip yourself with some fundamental understanding of this revolutionary breakthrough before betting against it.
Let's see who will have big win.
I don't have problems. I can tell you are a fake long. All your posts are full of negativity. Had you really read hundreds of papers and digested them, you wouldn't predict the sp for the revolutionary breakthrough.
Keep nagging and whining.
Let me ask you a very simple question since you have comprehension problem.
Among 33000 papers, can you find another treatment other than DCVax-L that can present hundreds of tumor-associated antigens to immune system and trigger sustainable and massive t cell infiltration into tumor site?
Now you have the question and search again.
"People here have reading problem."
Are you kidding me? You were bragging about reading hundreds of papers and documents on DCVax-L. The one who has serious reading problems might be you since I haven't seen a single post of yours which is original and seminal. All I can see is your nagging and whining on a different level. Either you cannot comprehend what you were reading or you are just a fake long. I tend to think the latter.
Why does NWBO need a PR department? All those patients who went through UK Specials Program didn't come to UK because of any PR. Was using polio to treat GBM aired on CBS 60 minutes? None of those patients had OS greater than three years. How many patients who received DCVax-L have OS greater than three years? A lot. You don't think DCVax-L deserves CBS 60 minutes after the approval?
It is a bad idea to bet against science. It would be terrible to bet against revolutionary science.
The longs won't read your posts because we the longs are allergic to BS. You can save BS to yourself.
That's all your so-called 20 yrs experience in biopharma can tell?
How much did Merck pay for Prometheus which had drugs for two targets with the market size of $24b in 2022? Did Merck terminate partnership with Seagen after spending $1.6b and turn to Daiichi for new partnership? Do Daiichi's ADCs in anyway outperform Seagen's? You would agree the results from the collaboration trial between Merck and Moderna are not impressive at all. In fact, the results from the neoadjuvant trial NADINA outperform the mRNA trial significantly. How's Merck's SC keytruda going? Not good at all. Merck hasn't released any PR on the trial even though the company uploaded the results to clinicaltrials.gov. Here is the link. See it yourself.
https://clinicaltrials.gov/study/NCT04956692
Merck's acquisition of Modifi Bio only shows how desperate the company wants to
Do you clue how many biosimilars of keytruda are under clinical trials? Here are some. You can find more on Opdivo. It is going to be very crowded market just like ADCs. This fact alone bodes extremely well for NWBO. You don't know why, do you?
https://www.clinicaltrialsarena.com/news/samsung-biopeis-keytruda-biosimilar-enters-phase-iii-trials/
https://www.lexology.com/library/detail.aspx?g=37efda82-adde-46fa-a1af-ef53c48d6b8b
https://www.bioworld.com/articles/709731-celltrion-seeks-us-ind-nod-for-keytruda-biosimilar-phase-iii?v=preview
https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-sandoz-group-melanoma-likelihood-of-approval/
Did you say that no one knows if Murthy still keeps the shares? Another lame BS.
You may not know that DCVax-L is the biggest breakthrough in medicine ever. But Murthy certainly knows. In fact, I think you know it too.
Here is a paper published in August with Nora Horick listed as one of the coauthors. I suppose you need to find another deceptive angle now.
https://ascopubs.org/doi/abs/10.1200/OP.24.00316
You mean prediction at whim?
You and your buddies have no clue about how revolutionary the technology is and yet you have the audacity to predict. You cannot be serious.
First, you have to admit DCVax-L is the biggest breakthrough in medicine. Then stop predicting.
Did you and your buddies cast negativity before that any future trials would also take five and ten years? You like to keep track of the post records from the longs. Go and search my posts to see if I pointed out that NWBO can simply use the certain biomarker to predict OS.
What did you and your buddies say when I posted all the records on Merck? The reason I stopped posting all the job hirings from BPs is that that part of DD has been done. All those BPs will and have to strike franchise deals with NWBO to adopt DCVax-L as the essential platform for the development of drug and vaccines.
My suggestion is: don't make frivolous and laughable predictions and do more homework to enlighten us how revolutionary DCVax-L is.
You can do the following which I doubt you will. Can you find any revenue on PLX3397 from Daiichi's reports? If not, why would all those BPs be interested in CSF1R-I?
https://www.daiichisankyo.com/investors/library/quarterly_result/
There are so many things that should stun you.
You never dreamed that NWBO could survive the OTC, reache a series of milestones, and file for application. Right?
Even in your wildest imagination, you never thought NWBO's technology could make DCs present hundreds of tumor-associated antigens to immune system to wipe out cancer cells. Right?
Did AF tell you ATL-DC isn't DCVax-L? Now you should know what he told you is lame BS. It stuns me why you are still his minion.
You haven't read Professor Keyoumars Ashkan's paper carefully, have you? Read it before making any prediction about the approval.
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml
Betting against the biggest breakthrough in medicine! What a childish move!
Dude,
Have I repeatedly reminded you that DCVax-L is revolutionary breakthrough and all your outdated BS measures which only fit for mediocre companies would lead you to nothing but debacle in your investment?
In the case of DCVax-L, given the magnitude of the breakthrough, all it matters is science! Everything else is just noise. Those NICE reimbursement, price model, etc are just BS created by you and your ilk in the hope that you can still deceive the longs.
I suggest you forget about Direct for now. You haven't digested all the data about DCVax-L. How could you predict anything about Direct? Ridiculous.
The reason you don't see the potential is that you don't have a good understanding about what is available in the public domain. I am certain those professionals from BPs should know.
Don't be surprised if one day the media hail DCVax-L as the biggest breakthrough in medicine ever since I said this to you already.
But we must be widely known among BPs. Why? Dendritic cells were never mentioned in their job postings. Not even once. But if you search on linkedin, each one of the BPs already recruited people with expertise on dendritic cells over the past a couple of years. For example, Dr. Lisa Butterfield joined Merck last March as Distinguished Scientist.
You must be desperate, which explains why you are using such a lightweight news to bash NWBO. Did you brag you had 20 years of experience in biopharma?
Basically you are saying each time Merck has an acquisition on oncology, Merck passes on NWBO.
You must be kidding and you are clueless about immunotherapy.
See this partnership between Flatiron and NICE? How many compassionate use cases on DCVax-L now? It must be over one thousand at minimum. You don't think NICE would collect data on those cases? You can stop your BS on NICE payment now.
https://healtheconomics.com/flatiron-health-collaborates-with-nice-on-rwe-for-cea/
https://www.appliedclinicaltrialsonline.com/view/flatiron-health-announces-new-partnership-in-the-uk
I bet it makes no sense to you that NWBO can survive on OTC for such a long time.
Wait and see. There are going to be a lot more that make no sense to you.
They did compete with each other. Everyone can see this if they read the NIH grant on the combo research with CSF1R-I included. This fact becomes more clear if one checks out the contact records of Timothy Cloughesy with both companies.
It doesn't matter if the two trials were materialized since we have the combo trial.
Does the combo trial use the technology licensed from NWBO? Absolutely. Then what do we need to worry about?
When did those BPs start acquiring ADCs? Was it before or after the ASCO presentation?
Thank goodness I have this one only and I am going to hold it for very long time.
Which NWBO long in sane category would listen to your BS?
You have been roaming on this board long enough to be able to read the following figure. Remind me what would be the last hurdle to cure GBM or the type of cancer whose immunosuppressive characteristics is dominated by TAMs.
Now go back to your boss and ask the following question: Why did Incyte reach Syndax in September 2021 to have a deal on CSF1R-I?
https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-and-incyte-announce-global-collaboration
You are a BS master. I never saw you talking about science. Not even once! Unless you really want to go broke, don't bet against revolutionary science.
Management is fantastic. Can't you see that LP let Merck pit against BMS? LP had the collaboration trial with Merck on colorectal cancer and in the meantime struck another deal with BMS on a much tougher target rGBM. Did you read ASCO presentation last year page by page? Dr.Bosch listed some of these tumor-associated peptides bonded with MHC Class I&II respectively. Did you search each one of them to see they were found before? IMO, the most important part of the whole presentation is hundreds of tumor-associated antigens can be presented by DCs educated by NWBO technology.
Can anyone believe that the management did such fabulous research behind the scene before the happening of the presentation? What we have seen is most likely the tip of an iceberg. All these research is the most essential treasure to let BPs bring big checkbook. It is LP's leadership that made such treasure a reality.